Veradermics is trading at $119.81, up 10.10%, after reporting that VDPHL01 met all primary and secondary endpoints in Phase 3 Study 304.
- The trial included 536 men with pattern hair loss.
- At six months, hair-count increases were 28.6 and 36.4 hairs/cm² for once- and twice-daily dosing, versus 6.6 for placebo.
- Live trading; volume information was not provided.